Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | INSR | P06213 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | ROS1 | P08922 | 1/20 | 0.42 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.42 |
| ▸ | PLK1 | P53350 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 3/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29661369 | 1.00 | SUV39H2 (0.45) | SUV39H2EGFRALKAURKAINSR | |
| Hydrochloric Acid SCHEMBL29367159 | 0.99 | SUV39H2 (0.44) | SUV39H2EGFRALKAURKAINSR | |
| SCHEMBL10206636 | 0.92 | ALK (0.44) | SUV39H2EGFRALKAURKAINSR | |
| SCHEMBL14240636 | 0.92 | NTSR1 (0.47) | SUV39H2ALKINSRIGF1RALDH1A1 | |
| SCHEMBL520746 | 0.92 | NTSR1 (0.47) | SUV39H2ALKINSRIGF1RALDH1A1 | |
| SCHEMBL24603026 | 0.89 | SUV39H2 (0.45) | SUV39H2EGFRALKAURKAINSR | |
| SCHEMBL3132203 | 0.88 | ACVR1 (0.45) | SUV39H2EGFRALKAURKAINSR | |
| SCHEMBL17411139 | 0.87 | FFAR4 (0.40) | SUV39H2EGFRALKAURKAINSR | |
| SCHEMBL28065615 | 0.85 | EGFR (0.42) | SUV39H2EGFRALKAURKAINSR | |
| SCHEMBL17265199 | 0.85 | ALDH1A1 (0.46) | ALDH1A1CYP3A4TSHRHSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10039775-B2 | Preparation method for antitumor drug AP26113 | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2018-08-07 | — | — | US | claimed |
| US-20180071324-A1 | PREPARATION METHOD FOR ANTITUMOR DRUG AP26113 | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2018-03-15 | — | — | US | claimed |
| EP-4725487-A1 | NOVEL COMPOUND AND PREPARATION METHOD THEREFOR | Astrion Inc. (KR) | 2026-04-15 | — | — | EP | disclosed |
| EP-4725488-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BRAIN TUMOR | Astrion Inc. (KR) | 2026-04-15 | — | — | EP | disclosed |
| WO-2025110777-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF BREAST CANCER | 주식회사 에스트리온 | 2025-05-30 | — | — | WO | disclosed |
| WO-2025110778-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HEAD AND NECK CANCER | 주식회사 에스트리온 | 2025-05-30 | — | — | WO | disclosed |
| US-20250171416-A2 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-05-29 | — | — | US | disclosed |
| WO-2024253476-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BRAIN TUMOR | 주식회사 에스트리온 | 2024-12-12 | — | — | WO | disclosed |
| WO-2024253475-A1 | NOVEL COMPOUND AND PREPARATION METHOD THEREFOR | 주식회사 에스트리온 | 2024-12-12 | — | — | WO | disclosed |
| US-20240352000-A1 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RES INST CHEMICAL TECH (KR) | 2024-10-24 | — | — | US | disclosed |
| EP-4371983-A1 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | Korea Research Institute of Chemical Technology (KR) | 2024-05-22 | — | — | EP | disclosed |
| WO-2010138576-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | disclosed |
| WO-2008150799-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071324-A1 | PREPARATION METHOD FOR ANTITUMOR DRUG AP26113 | ATG13, CMPK1, USP13 | SUV39H2 3150/4885EGFR 1302/4885ALK 516/4885 |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | SUV39H2 2240/4885EGFR 491/4885ALK 144/4885 |
| US-10039775-B2 | Preparation method for antitumor drug AP26113 | ATG13, CMPK1, USP13 | SUV39H2 3150/4885EGFR 1302/4885ALK 516/4885 |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | SUV39H2 2240/4885EGFR 491/4885ALK 144/4885 |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | TYMS, TYMP, DPYD | SUV39H2 3074/4885EGFR 2285/4885ALK 3200/4885 |
| US-20240352000-A1 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | WEE2, WEE1, ERBB2 | SUV39H2 3174/4885EGFR 6/4885ALK 1560/4885 |
| US-20250171416-A2 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | WEE2, WEE1, ERBB2 | SUV39H2 3174/4885EGFR 6/4885ALK 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.